CoChat

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

This multicenter, first-in-human Phase 1 study (NCT04956640) evaluated olomorasib (LY3537982), a next-generation KRAS G12C inhibitor designed to enhance target occupancy at low absolute exposures. In total, data from 195 patients are reported: Phase 1a dose escalation ( n = 112) assessed olomorasib monotherapy at 50, 100, 150 or 200 mg BID across KRAS G12C-mutant advanced solid tumors; the primary objective was to determine the recommended Phase 2 dose (RP2D) based on dose-limiting toxicities (DLTs). No DLTs occurred, and 150 mg BID was selected as the RP2D. The primary objective for the Phase 1b dose expansion ( n = 83) was to evaluate the safety and tolerability of olomorasib in specific KRAS G12C-mutant tumor types. Olomorasib was well tolerated, with predominantly grade 1–2 treatment-related adverse events (TRAEs) and infrequent grade 3 TRAEs; no grade 4/5 TRAEs occurred. Secondary objectives evaluated the antitumor activity of olomorasib. Among 168 efficacy-evaluable patients, the ORR and median PFS were both higher in non-CRC solid tumors compared to CRC, including in patients with NSCLC who previously received a KRAS G12C inhibitor. Intracranial responses were observed in patients with untreated, active brain metastases. This may support the potential of next-generation KRAS G12C inhibitors to overcome limitations of earlier agents and justify further investigation of combination therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-026-69943-7

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 LOXO-RAS-20001 Trial Schema. Phase 1a included dose escalation and backfill cohorts, while Phase 1b included exploratory monotherapy expansion cohorts in select populations. a Includes solid tumors that are not NSCLC, CRC, or Pancreatic cancer. Abbreviations: BID twice a day, CRC colorectal cancer, NSCLC non-small cell lung cancer.
Fig. 1 LOXO-RAS-20001 Trial Schema. Phase 1a included dose escalation and backfill cohorts, while Phase 1b included exploratory monotherapy expansion cohorts in select populations. a Includes solid tumors that are not NSCLC, CRC, or Pancreatic cancer. Abbreviations: BID twice a day, CRC colorectal cancer, NSCLC non-small cell lung cancer.CC BY · PubMed Central
Fig. 2 Anti-tumor activity of olomorasib. Studying both RECIST response (A) and ctDNA response (B), activity was greater in non-CRC solid tumors (left) versus CRC (right). Consistent RECIST responses were seen in NSCLC, pancreatic cancer, and other solid tumors. ctDNA clearance was common in non-CRC solid tumors, and was apparent in patients with and without a RECIST response. ‡ Indicates patient with ctDNA increase >100%. Source data are provided as a Source Data file. Abbreviations: CR complete response, CRC colorectal cancer, NE not evaluable, NSCLC non-small cell lung cancer, PANC pancreatic, PD progressive disease, PR partial response, SD stable disease, uPR unconfirmed partial response.
Fig. 2 Anti-tumor activity of olomorasib. Studying both RECIST response (A) and ctDNA response (B), activity was greater in non-CRC solid tumors (left) versus CRC (right). Consistent RECIST responses were seen in NSCLC, pancreatic cancer, and other solid tumors. ctDNA clearance was common in non-CRC solid tumors, and was apparent in patients with and without a RECIST response. ‡ Indicates patient with ctDNA increase >100%. Source data are provided as a Source Data file. Abbreviations: CR complete response, CRC colorectal cancer, NE not evaluable, NSCLC non-small cell lung cancer, PANC pancreatic, PD progressive disease, PR partial response, SD stable disease, uPR unconfirmed partial response.CC BY · PubMed Central
Fig. 3 Intracranial activity of olomorasib. Of 11 patients enrolled with NSCLC and active, untreated brain metastases, on-treatment brain MRI was available for 9 (A) and demonstrated durable activity in a subset of patients. In one representative patient with NSCLC metastatic to brain and progression following systemic therapy and radiation (B), on-treatment brain MRI after 6 weeks showed resolution of measurable brain metastases. Source data are provided as a Source Data file. Abbreviations: MRI magnetic resonance imaging, NSCLC non-small cell lung cancer.
Fig. 3 Intracranial activity of olomorasib. Of 11 patients enrolled with NSCLC and active, untreated brain metastases, on-treatment brain MRI was available for 9 (A) and demonstrated durable activity in a subset of patients. In one representative patient with NSCLC metastatic to brain and progression following systemic therapy and radiation (B), on-treatment brain MRI after 6 weeks showed resolution of measurable brain metastases. Source data are provided as a Source Data file. Abbreviations: MRI magnetic resonance imaging, NSCLC non-small cell lung cancer.CC BY · PubMed Central
Fig. 4 Activity of olomorasib after prior KRAS G12C inhibitor (KRAS G12Ci) treatment. Swimmer plot (A) demonstrates the potential for durable benefit from olomorasib in 38 patients previously treated with a KRAS G12Ci, with an ORR of 42% and median PFS of 8.2 months. Prolonged benefit was apparent in some patients, especially those who discontinued a prior KRAS G12Ci due to toxicity. B While ctDNA analysis identified putative resistance mutations present after prior KRAS G12Ci treatment there was no enrichment in non-responders. Serial ctDNA analysis (C) demonstrated a KRAS G12C molecular response (red) in most patients with putative resistance mutations (blue), questioning their biologic relevance. Source data are provided as a Source Data file. Abbreviations: ctDNA circulating tumor DNA, G12Ci G12C inhibitor, ORR overall response rate, PFS progression-free survival.
Fig. 4 Activity of olomorasib after prior KRAS G12C inhibitor (KRAS G12Ci) treatment. Swimmer plot (A) demonstrates the potential for durable benefit from olomorasib in 38 patients previously treated with a KRAS G12Ci, with an ORR of 42% and median PFS of 8.2 months. Prolonged benefit was apparent in some patients, especially those who discontinued a prior KRAS G12Ci due to toxicity. B While ctDNA analysis identified putative resistance mutations present after prior KRAS G12Ci treatment there was no enrichment in non-responders. Serial ctDNA analysis (C) demonstrated a KRAS G12C molecular response (red) in most patients with putative resistance mutations (blue), questioning their biologic relevance. Source data are provided as a Source Data file. Abbreviations: ctDNA circulating tumor DNA, G12Ci G12C inhibitor, ORR overall response rate, PFS progression-free survival.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Metadata

Authors
Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., Shimizu, T., Reddy Ammakkanavar, N., Spira, A., Gomez-Roca, C., Patnaik, A., Cosman, R., Bodor, J. N., Nagasaka, M., You, A. X., McNeely, S. C., Peter, R., Fink, A., Chen, A., Oxnard, G. R., Willard, M. D., Kuboki, Y., & Koyama, T.
Affiliations
  • Institut Gustave Roussy (FR)
  • Massachusetts General Hospital (US)
  • Centre Léon Bérard (FR)
  • National Cancer Center (KR)
  • Yale University (US)
  • NYU Langone Health (US)
  • University Health Network (CA)
  • UPMC Hillman Cancer Center (US)
  • Kansai Medical University (JP)
  • Virginia Cancer Specialists (US)
  • South Texas Accelerated Research Therapeutics (US)
  • UNSW Sydney (AU)
  • Fox Chase Cancer Center (US)
  • University of California, Irvine (US)
  • Eli Lilly (United States) (US)
  • National Cancer Centre Japan (JP)
  • National Cancer Center Hospital (JP)
Venue
Nature Communications
Published
2026-03-12
Volume
17
Issue
1
ISSN
2041-1723 (ISSN-L)
OpenAlex
W7135017986
Cited by
13
References
31
Citations by year
2026: 13
FWCI
26.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
This work is partially supported by a National Cancer Institute/ National Institutes of Health Cancer Center Support grant to Memorial Sloan Kettering Cancer Center
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
KRAS G12C inhibitors, dose-limiting toxicity, recommended phase 2 dose, anticancer activity, non-small cell lung cancer, colorectal cancer, brain metastases, intracranial response, treatment-related adverse events, first-in-human
MeSH terms
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzimidazoles, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study. https://app.cochat.ai/papers/10.1038/s41467-026-69943-7
The paper
Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., Shimizu, T., Reddy Ammakkanavar, N., Spira, A., Gomez-Roca, C., Patnaik, A., Cosman, R., Bodor, J. N., Nagasaka, M., You, A. X., . . . Koyama, T. (2026). Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study. Nature Communications. https://doi.org/10.1038/s41467-026-69943-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.